S
Sulekha Karki
Researcher at Daiichi Sankyo
Publications - 7
Citations - 435
Sulekha Karki is an academic researcher from Daiichi Sankyo. The author has contributed to research in topics: Amlodipine & Olmesartan. The author has an hindex of 5, co-authored 7 publications receiving 409 citations.
Papers
More filters
Journal ArticleDOI
The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study
TL;DR: The combination of OM and AML was effective and well tolerated in this adult population with hypertension and was associated with dose-dependent reductions in SeDBP that were significantly greater than the reductions with the corresponding component monotherapies.
Journal ArticleDOI
Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia.
Evan A. Stein,A. David Marais,Tamas Szamosi,Frederick J. Raal,Daniel Schurr,Elaine M. Urbina,Paul N. Hopkins,Sulekha Karki,Jianbo Xu,Soamnauth Misir,Michael Melino +10 more
TL;DR: Colesevelam significantly lowered LDL-cholesterol levels in children with heFH and these treatment effects were maintained during period III.
Journal ArticleDOI
Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension.
TL;DR: Combination antihypertensive therapy with AML+OM±HTCZ, up‐titrated as necessary, allowed a majority of patients to achieve BP goal, and study medication was safe and well tolerated.
Journal ArticleDOI
Long-term efficacy of a combination of amlodipine and olmesartan medoxomil±hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial
TL;DR: The combination of AML+OM±HCTZ was efficacious, safe and well tolerated by these subgroups and decreased from baseline for all treatments in each prespecified subgroup.
Journal ArticleDOI
Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use.
TL;DR: After 8 weeks of treatment, the combination of amlodipine + OM is safe and efficacious, irrespective of baseline hypertension stage or prior antihypertensive medication use, and produced the greatest mean BP reductions in patients with baseline SeSBP ≥180 mm Hg.